Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03603730 · ClinicalTrials.gov registry record · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
A NA study of Gastroparesis and Dyspepsia, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT03603730: Recruiting NA study of Gastroparesis and Dyspepsia, sponsored by Massachusetts General Hospital.
NCT03603730 is a NA study of Gastroparesis and Dyspepsia that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 65 participants, below the 301-participant average among 44 other Gastroparesis trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03603730, a NA study of Gastroparesis and Dyspepsia, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
Explore the effects of auricular transcutaneous vagal nerve stimulation (taVNS) on brain and stomach outcomes in functional dyspepsia and gastroparesis patients.
Primary Outcome
NTS connectivity
Conditions Studied
Interventions
- DEVICE taVNS
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2018-11-30 |
| Est. Completion | 2028-03-31 |
| Phase | NA |
What NCT03603730 shows while recruiting
NCT03603730 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 301-participant average among 44 other Gastroparesis trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Gastroparesis appearing as the primary indexed condition, and to 1 intervention - of which taVNS is the first listed.
NCT03603730 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03603730 about?
NCT03603730 is a clinical study titled "Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis". Explore the effects of auricular transcutaneous vagal nerve stimulation (taVNS) on brain and stomach outcomes in functional dyspepsia and gastroparesis patients.
What is the current status of trial NCT03603730?
This trial is currently recruiting. It is a NA study. The enrollment target is 65 participants. The study started on 2018-11-30. Estimated completion is 2028-03-31.
What conditions does trial NCT03603730 study?
This clinical trial studies the following conditions: Gastroparesis, Dyspepsia.
What interventions are being tested in trial NCT03603730?
The interventions under investigation include: taVNS (DEVICE).
Who is sponsoring clinical trial NCT03603730?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03603730 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroparesis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03603730's enrollment target sits among peer trials
65 23rd of 44 higher than 22 of 44 other Gastroparesis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroparesis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Body Surface Gastric Mapping in Assessing the Clinical Success of G-POEM
RECRUITING · NA
-
Compassionate Use of Domperidone for Refractory Gastroparesis
RECRUITING · NA
-
Central and Peripheral Effects of Cognitive Behavioral Therapy on Brain-Gut Axis Signaling in Gastroparetic Patients
RECRUITING · NA
-
Transpyloric Stenting As a Predictor for G-POEM for Refractory Gastroparesis
RECRUITING · NA
-
Study of Enhanced Programming Stimulation with the Enterra® Therapy System
RECRUITING · NA
-
Study of Enterra Programming with Nocturnal Cycling in Gastroparetics
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
- NCT04028063 · 65 participants · Phase 2
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI